# US 12,006,501 B2 · Composition of drug targets and method of using thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,006,501 B2
- Document ID: US12006501B2
- Status: Granted
- Kind: B2
- Application number: 16/759,362
- Filed: 2017-12-13
- Published: 2023-06-22
- Granted: 2024-06-11
- Earliest claimed: 2017-10-27
- Assignees: Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
- Applicants: Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
- Inventors: Xiaolu Huang; Xiao Liang; Qingfeng Li; Bangda Chai
- Web page: https://patentgrep.com/patent/US12006501B2

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/31: Combination therapy
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12Y 502/01008: Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

A composition of drug targets and the method of using thereof. The composition comprises a vector and a drug using FKBP10 and PCOLCE genes and/or the encoded proteins thereof as drug targets.

## Claims

### Claim 1

A drug combination comprising siRNAs that target human or mouse FK506 binding protein 10 (FKBP10) and siRNAs that target human or mouse procollagen C-endopeptidase enhancer (PCOLCE) transcript,
wherein sequence of the siRNA for human FKBP10 mRNA are as follows:
sense strand: SEQ ID NO: 1, 5′-GAAGGAAGAUUAUCAUCCCUCCAUU-3′;
antisense strand: SEQ ID NO: 2, 5′-AAUGGAGGGAUGAUAAUCUUCCUUC-3′;
wherein sequence of the siRNA for mouse FKBP10 mRNA are as follows:
sense strand: SEQ ID NO: 3, 5′-CCACACCUACAAUACCUAUTT-3′;
antisense strand: SEQ ID NO: 4, 5′-AUAGGUAUUGUAGGUGUGGTT-3′;
wherein sequence of the siRNA for human PCOLCE mRNA are as follows:
sense strand: SEQ ID NO: 5, 5′-CCUUCCUCCAGAGAGCUUU-3′;
antisense strand: SEQ ID NO: 6, 5′-AAAGCUCUCUGGAGGAAGG-3′;
wherein sequence of the siRNA for mouse PCOLCE mRNA are as follows:
sense strand: SEQ ID NO: 7, 5′-CCUGGCAACCAAGUGACUU-3′;
antisense strand: SEQ ID NO: 8, 5′-AAGUCACUUGGUUGCCAGG-3′.

### Claim 2 (depends on 1)

A method of administering the drug combination according to claim 1, wherein the drug combination is administered by local injection or smearing.

### Claim 3 (depends on 1)

The drug combination according to claim 1 comprising a vector, wherein the vector is a histidine polypeptide, a lysine polypeptide, or a branched histidine-lysine copolymer polypeptide.

### Claim 4 (depends on 1)

A method of treating hyperplastic pathological scar comprising administering the drug combination according to claim 1.